Clinical efficacy of triamcinolone acetonide and Ranibizumab in the treatment of diabetic diffuse macular edema

• Main Authors: Bi-Hua Xie, Yu He, Mei Xin, Zhuo Chen
• Format: Article
• Language: English
• Published: Press of International Journal of Ophthalmology (IJO PRESS) 2018-06-01
• Series: Guoji Yanke Zazhi
• Subjects: diffuse diabetic macular edema; triamcinolone acetonide; ranibizumab; laser photocoagulation
• Online Access: http://ies.ijo.cn/cn_publish/2018/6/201806025.pdf

AIM:To compare the clinical curative effect of triamcinolone acetonide and Ranibizumab on diffuse diabetic macular edema(DME). <p>METHODS: We collected 84 cases of patients with diffuse DME treated in our hospital from February 2016 to May 2017. According to 1:1 matching method, they were divided into Ⅰ, Ⅱ groups. They were all treated with laser photocoagulation. Preoperative auxiliary application of triamcinolone acetonide was given to Group Ⅰ, while Group Ⅱ received preoperative application of ranibizumab. After treatment, the efficacy of the two groups were analyzed and compared. <p>RESULTS: The total clinical efficiency of Group Ⅱ at 3mo after treatment was 93%, higher than that of Group Ⅰ(77%; <i>χ</i>²=4.981, <i>P</i>=0.025). Compared with before treatment, BCVA and CMT of the two groups at each time after treatment were significantly improved(<i>P</i><0.05). BCVA of Group Ⅱ at 1 and 3mo after treatment was better than that of Group Ⅰ(<i>P</i><0.05); CMT of Group Ⅱ at 1, 3 and 6mo after treatment improved more than that of Group Ⅰ, with significant difference(<i>P</i><0.05); occurrence rate of adverse reactions Group Ⅰ and Group Ⅱ were 17% and 13% with no significant statistical difference(<i>χ</i>²=0.243, <i>P</i>=0.621). There were no serious adverse reactions such as retinal detachment, endophthalmitis or cataract in the two groups. <p>CONCLUSION: Compared with triamcinolone acetonide, the effect of ranibizumab on diffuse diabetic macular edema is better, and has high clinical value.